The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies

被引:29
|
作者
Faia, Kerrie [1 ,2 ]
White, Kerry [1 ]
Murphy, Erin [1 ]
Proctor, Jennifer [1 ]
Pink, Melissa [1 ]
Kosmider, Nicole [1 ]
McGovern, Karen [1 ]
Kutok, Jeffery [1 ]
机构
[1] Infin Pharmaceut Inc, Cambridge, MA 02139 USA
[2] Blueprint Med Inc, Cambridge, MA 02139 USA
来源
PLOS ONE | 2018年 / 13卷 / 08期
关键词
B-CELL; 3-KINASE; PI3K-DELTA; AUTOIMMUNE; PI3K-GAMMA; CAL-101; SUBUNIT; SIGNALS; GAMMA; PI3K;
D O I
10.1371/journal.pone.0200725
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Duvelisib is an orally active dual inhibitor of PI3K-delta and PI3K-gamma in clinical development in hematologic malignancies (HM). To identify novel pairings for duvelisib in HM, it was evaluated alone and in combination with 35 compounds comprising a diverse panel of standardof-care agents and emerging drugs in development for HM. These compounds were tested in 20 cell lines including diffuse large B-cell, follicular, T-cell, and mantle cell lymphomas, and multiple myeloma. Single agent activity was seen in fourteen cell lines, with a median GI(50) of 0.59 mu M. A scalar measure of the strength of synergistic drug interactions revealed a synergy hit rate of 19.3% across the matrix of drug combinations and cell lines. Synergy with duvelisib was prominent in lymphoma lines with approved and emerging drugs used to treat HM, including dexamethasone, ibrutinib, and the BCL-2 inhibitor venetoclax. Western blotting revealed that certain duvelisib-treated cell lines showed inhibition of phosphorylated (p) AKT at serine 473 only out to 12 hours, with mTORC2 dependent re-phosphorylation of pAKT evident at 24 hours. Combination with dexamethasone or ibrutinib, however, prevented this reactivation leading to durable inhibition of pAKT. The combination treatments also inhibited downstream signaling effectors pPRAS40 and pS6. The combination of duvelisib with dexamethasone also significantly reduced p-4EBP1, which controls cap dependent translation initiation, leading to decreased levels of c-MYC 6 hours after treatment. In support of the in vitro studies, in vivo xenograft studies revealed that duvelisib in combination with the mTOR inhibitor everolimus led to greater tumor growth inhibition compared to single agent administration. These data provide a rationale for exploring multiple combinations in the clinic and suggest that suppression of mTOR-driven survival signaling may be one important mechanism for combination synergy.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] TGR-1202: A Novel, Targeted PI3Kδ Inhibitor in Multiple Myeloma
    Vakkalanka, Swaroop
    Viswanadha, Srikant
    Boise, Lawrence H.
    Sportelli, Peter
    Miskin, Hari
    Lonial, Sagar
    BLOOD, 2012, 120 (21)
  • [32] Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
    Nylander, S.
    Kull, B.
    Bjorkman, J. A.
    Ulvinge, J. C.
    Oakes, N.
    Emanuelsson, B. M.
    Andersson, M.
    Skarby, T.
    Inghardt, T.
    Fjellstrom, O.
    Gustafsson, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) : 2127 - 2136
  • [33] Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
    Jin, Feng
    Gao, Yuying
    Zhou, Huafeng
    Fang, Lorna
    Li, Xiaoming
    Ramanathan, Srini
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (01) : 89 - 98
  • [34] Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies
    Feng Jin
    Yuying Gao
    Huafeng Zhou
    Lorna Fang
    Xiaoming Li
    Srini Ramanathan
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 89 - 98
  • [35] Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies
    Jin, Feng
    Zhou, Huafeng
    Fang, Lorna
    Li, Xiaoming
    Newcomb, Terry
    Dansey, Roger
    Ramanathan, Srini
    BLOOD, 2013, 122 (21)
  • [36] Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"
    Keegan, Niamh M.
    Furney, Simon J.
    Walshe, Janice M.
    Gullo, Giuseppe
    Kennedy, M. John
    Smith, Diarmuid
    McCaffrey, John
    Kelly, Catherine M.
    Egan, Keith
    Kerr, Jennifer
    Given, Mark
    O'Donovan, Peter
    Hernando, Andres
    Teiserskiene, Ausra
    Parker, Imelda
    Kay, Elaine
    Farrelly, Angela
    Carr, Aoife
    Calzaferri, Giulio
    McDermott, Ray
    Keane, Maccon M.
    Grogan, Liam
    Breathnach, Oscar
    Morris, Patrick G.
    Toomey, Sinead
    Hennessy, Bryan T.
    CANCERS, 2021, 13 (06) : 1 - 13
  • [37] Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors
    Toska, Eneda
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2016, 22 (09) : 2099 - 2101
  • [38] Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα
    Kim, Jinhee
    Hong, Seunghee
    Hong, Sungwoo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6977 - 6981
  • [39] Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma
    Harrison, Douglas
    Gill, Jonathan
    Roth, Michael
    Hingorani, Pooja
    Zhang, Wendong
    Teicher, Beverly
    Earley, Eric
    Erickson, Stephen
    Gatto, Gregory
    Kumasheva, Raushan
    Houghton, Peter
    Smith, Malcolm
    Kolb, E. Anders
    Gorlick, Richard
    PEDIATRIC BLOOD & CANCER, 2023, 70 (01)
  • [40] Bleeding response induced by anti-thrombotic doses of phosphoinositide 3-kinase (PI3K) inhibitor in mice
    Bird, J. E.
    Smith, P. L.
    Bostwick, J. S.
    Schumacher, W. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 659 - 659